Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.45 |
| ▸ | GPR4 | P46093 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3317688 | 0.95 | CTSK (0.54) | CTSKCTSLCTSSCTSBTBK1 | |
| SCHEMBL8270035 | 0.93 | CTSK (0.51) | CTSKCTSLCTSSCTSBTBK1 | |
| SCHEMBL8270732 | 0.90 | CTSK (0.47) | CTSKCTSLCTSSCTSBHDAC6 | |
| SCHEMBL5790992 | 0.90 | CTSK (0.47) | CTSKCTSLCTSSCTSBTBK1 | |
| SCHEMBL8270522 | 0.90 | CTSK (0.51) | CTSKCTSLCTSSCTSBTBK1 | |
| SCHEMBL8270031 | 0.88 | CTSK (0.72) | CTSKCTSLCTSSCTSBTBK1 | |
| SCHEMBL5791397 | 0.88 | CTSK (0.48) | CTSKCTSLCTSSCTSB | |
| Trifluoroacetic Acid SCHEMBL5794393 | 0.86 | CTSK (0.44) | CTSKCTSLCTSSCTSBHDAC6 | |
| Trifluoroacetic Acid SCHEMBL5791678 | 0.85 | CTSK (0.47) | CTSKCTSLCTSSCTSBTBK1 | |
| SCHEMBL8270467 | 0.85 | CTSK (0.48) | CTSKCTSLCTSSCTSBGPR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-2028182-A1 | Cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-1972630-A1 | Purines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-24 | — | — | EP | disclosed |
| US-20070232586-A1 | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof | OHMOTO KAZUYUKI | 2007-10-04 | — | — | US | disclosed |
| EP-1739081-A1 | HYDRAZINO-SUBSTITUTED HETEROCYCLIC NITRILE COMPOUNDS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006027211-A1 | 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232586-A1 | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof | CTRL, PRSS1, CTSZ | CTSK 66/4885CTSL 135/4885CTSS 9/4885 |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | CPN1, SERPINB1, PNP | CTSK 135/4885CTSL 31/4885CTSS 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.